stabl commerci mix
lower end manag expect
report adj ep est/consensu howev adjust
ebitda-nci estim lower end manag
expect lower expect treatment higher self-fund employe
insur cost expect lower end guidanc
rang year posit compani highlight continu stabil
commerci payer mix well receiv fm point
declin overal quarter mix lower adjust ebitda-nci
estim updat outlook unchang po base
ebitda-nci vs previous driven good visibl growth next year
develop pipelin grew quarter reiter buy rate stabil
commerci environ upsid potenti clinic open
revenu estim de novo slip
patient servic oper revenu increas y/i
est/consensu lower expect vol price non-acquir treatment growth
deceler normal treatment growth slightli
manag expect lower full year treatment growth
expect midpoint site open quarter
patient care cost higher expect better
ebitda margin y/i wors estimate
patient care cost per treatment higher expect per
treatment came estimate meanwhil minor interest came
lower estimate trend
pipelin clinic growth ramp
open two de novo center estim compani may
face delay howev impli growth ramp
rel easi comp head sign clinic schedul open
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
nation provid dialysi servic
compani oper dialysi clinic serv
patient chronic kidney failur also known
differenti model oper
physician partnership model partner
nephrologist develop oper dialysi
dialysi stabl recur busi
defens area health care facil
addit compani jv model help
recruit nephrologist facilit open
de novo clinic strong econom
high margin final see upsid
recent oper initi epo
po base ebitda-nci estim view uniqu
growth strong ebitda margin warrant premium multipl health care facil
growth end-stag renal diseas esrd lack altern result
above-averag demand dialysi next sever year
downsid risk manag care repres vast major profit dialysi
provid declin number insur rate pressur commerci
contract could pressur margin addit medicar rate lacklust
could regulatori scrutini compani jv structur time
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
